Ranbaxy Pharmaceuticals Inc. is conducting a voluntary recall of all lots of nitrofurantoin (monohydrate/macrocrystals) capsules, 100 mg, currently on the market in the United States.

Nitrofurantoin is an antibiotic indicated for the treatment of urinary tract infections.

Although certain lots of the product were determined to not be in conformity with the approved laboratory specifications, Ranbaxy said it decided to recall all lots as a matter of caution. The company is continuing to look into the cause of such non-conformity.

The recall is being conducted in coordination with the FDA and will be a retail-level recall. While the recalled product is unlikely to produce any serious adverse health effects, there is "a remote possibility that the non-conforming product may increase the incidence" of nausea and vomiting, according to a Ranbaxy statement.